{"id":"W4247051977","doi":"10.1200/jco.2013.31.15_suppl.tps8612","title":"Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; ABVD; Dacarbazine; Internal medicine; Oncology; Vinblastine; Chemotherapy regimen; Regimen; Bleomycin; Chemotherapy; Vincristine; CD30; Lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001660266,0.001475125,0.002389787,0.0004358619,0.0004188959,0.001315185,0.00126194,0.001541721,0.004529913],"category_scores_gemma":[0.0009504129,0.0007489231,0.001430016,0.0004319571,0.001080792,0.001050275,0.0003465461,0.004598301,0.001279859],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001309664,"about_ca_system_score_gemma":0.001681139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001685515,"about_ca_topic_score_gemma":0.003677209,"domain_scores_codex":[0.9995913,0.0001904469,0.00001654165,0.00008100604,0.0000379672,0.00008274186],"domain_scores_gemma":[0.9989744,0.0001590034,0.0001471811,0.00007222215,0.00006205151,0.0005851057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8178745,0.1102114,0.002093548,0.0005324703,0.001285168,0.0001476797,0.0002054511,0.002663172,0.02171345,0.0002982878,0.002486875,0.04048806],"study_design_scores_gemma":[0.532856,0.4558855,0.005084937,0.00003406926,0.0004150161,0.0001323121,0.00005439432,0.001480294,0.00201908,0.0002441431,0.001773227,0.00002093561],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889642,0.002751343,0.0008257128,0.0005520608,0.000411373,0.003264967,0.001222277,0.0001182989,0.001889779],"genre_scores_gemma":[0.9877939,0.002149879,0.001584959,0.0008878467,0.0002274984,0.002437338,0.001895746,0.00003485162,0.002988003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004529913,"threshold_uncertainty_score":0.01515412,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09144301180543674,"score_gpt":0.4451930388676109,"score_spread":0.3537500270621742,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}